245 related articles for article (PubMed ID: 32843673)
1. Drug-encapsulated blend of PLGA-PEG microspheres: in vitro and in vivo study of the effects of localized/targeted drug delivery on the treatment of triple-negative breast cancer.
Jusu SM; Obayemi JD; Salifu AA; Nwazojie CC; Uzonwanne V; Odusanya OS; Soboyejo WO
Sci Rep; 2020 Aug; 10(1):14188. PubMed ID: 32843673
[TBL] [Abstract][Full Text] [Related]
2. Targeted drug-loaded PLGA-PCL microspheres for specific and localized treatment of triple negative breast cancer.
Nwazojie CC; Obayemi JD; Salifu AA; Borbor-Sawyer SM; Uzonwanne VO; Onyekanne CE; Akpan UM; Onwudiwe KC; Oparah JC; Odusanya OS; Soboyejo WO
J Mater Sci Mater Med; 2023 Aug; 34(8):41. PubMed ID: 37530973
[TBL] [Abstract][Full Text] [Related]
3. Degradable porous drug-loaded polymer scaffolds for localized cancer drug delivery and breast cell/tissue growth.
Obayemi JD; Jusu SM; Salifu AA; Ghahremani S; Tadesse M; Uzonwanne VO; Soboyejo WO
Mater Sci Eng C Mater Biol Appl; 2020 Jul; 112():110794. PubMed ID: 32409024
[TBL] [Abstract][Full Text] [Related]
4. LHRH-Conjugated Drugs as Targeted Therapeutic Agents for the Specific Targeting and Localized Treatment of Triple Negative Breast Cancer.
Obayemi JD; Salifu AA; Eluu SC; Uzonwanne VO; Jusu SM; Nwazojie CC; Onyekanne CE; Ojelabi O; Payne L; Moore CM; King JA; Soboyejo WO
Sci Rep; 2020 May; 10(1):8212. PubMed ID: 32427904
[TBL] [Abstract][Full Text] [Related]
5. In-vivo studies of targeted and localized cancer drug release from microporous poly-di-methyl-siloxane (PDMS) devices for the treatment of triple negative breast cancer.
Eluu SC; Obayemi JD; Salifu AA; Yiporo D; Oko AO; Aina T; Oparah JC; Ezeala CC; Etinosa PO; Ugwu CM; Esimone CO; Soboyejo WO
Sci Rep; 2024 Jan; 14(1):31. PubMed ID: 38167999
[TBL] [Abstract][Full Text] [Related]
6. LHRH-Targeted Redox-Responsive Crosslinked Micelles Impart Selective Drug Delivery and Effective Chemotherapy in Triple-Negative Breast Cancer.
Xiao K; Liu Q; Suby N; Xiao W; Agrawal R; Vu M; Zhang H; Luo Y; Li Y; Lam KS
Adv Healthc Mater; 2021 Feb; 10(3):e2001196. PubMed ID: 33200571
[TBL] [Abstract][Full Text] [Related]
7. The characterization of paclitaxel-loaded microspheres manufactured from blends of poly(lactic-co-glycolic acid) (PLGA) and low molecular weight diblock copolymers.
Jackson JK; Hung T; Letchford K; Burt HM
Int J Pharm; 2007 Sep; 342(1-2):6-17. PubMed ID: 17555895
[TBL] [Abstract][Full Text] [Related]
8. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
[TBL] [Abstract][Full Text] [Related]
9. Tumor-targeted paclitaxel-loaded folate conjugated poly(ethylene glycol)-poly(L-lactide) microparticles produced by supercritical fluid technology.
Huang X; Zhang Y; Yin G; Pu X; Liao X; Huang Z; Chen X; Yao Y
J Mater Sci Mater Med; 2015 Feb; 26(2):95. PubMed ID: 25649516
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel molecularly imprinted polymer-PEG-folate nanoparticles for targeting anticancer delivery: Characterization and cellular cytotoxicity.
Esfandyari-Manesh M; Darvishi B; Ishkuh FA; Shahmoradi E; Mohammadi A; Javanbakht M; Dinarvand R; Atyabi F
Mater Sci Eng C Mater Biol Appl; 2016 May; 62():626-33. PubMed ID: 26952466
[TBL] [Abstract][Full Text] [Related]
11. Graphene oxide stabilized by PLA-PEG copolymers for the controlled delivery of paclitaxel.
Angelopoulou A; Voulgari E; Diamanti EK; Gournis D; Avgoustakis K
Eur J Pharm Biopharm; 2015 Jun; 93():18-26. PubMed ID: 25817600
[TBL] [Abstract][Full Text] [Related]
12. Hemocompatibility of folic-acid-conjugated amphiphilic PEG-PLGA copolymer nanoparticles for co-delivery of cisplatin and paclitaxel: treatment effects for non-small-cell lung cancer.
He Z; Shi Z; Sun W; Ma J; Xia J; Zhang X; Chen W; Huang J
Tumour Biol; 2016 Jun; 37(6):7809-21. PubMed ID: 26695149
[TBL] [Abstract][Full Text] [Related]
13. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
[TBL] [Abstract][Full Text] [Related]
14. A Photopolymerized Semi-Interpenetrating Polymer Networks-Based Hydrogel Incorporated with Nanoparticle for Local Chemotherapy of Tumors.
Wang Y; Li Q; Zhou JE; Tan J; Li M; Xu N; Qu F; Chen J; Li J; Wang J; Liang Z; Yu L; Wang Y; Yan Z
Pharm Res; 2021 Apr; 38(4):669-680. PubMed ID: 33796952
[TBL] [Abstract][Full Text] [Related]
15. Tumor-Targeting Micelles Based on Linear-Dendritic PEG-PTX
Zhang Y; Lu Y; Zhang Y; He X; Chen Q; Liu L; Chen X; Ruan C; Sun T; Jiang C
Mol Pharm; 2017 Oct; 14(10):3409-3421. PubMed ID: 28832164
[TBL] [Abstract][Full Text] [Related]
16. Development of a novel morphological paclitaxel-loaded PLGA microspheres for effective cancer therapy: in vitro and in vivo evaluations.
Zhang Z; Wang X; Li B; Hou Y; Yang J; Yi L
Drug Deliv; 2018 Nov; 25(1):166-177. PubMed ID: 29299936
[TBL] [Abstract][Full Text] [Related]
17. Luteinizing hormone-releasing hormone peptide tethered nanoparticulate system for enhanced antitumoral efficacy of paclitaxel.
Ghanghoria R; Tekade RK; Mishra AK; Chuttani K; Jain NK
Nanomedicine (Lond); 2016 Apr; 11(7):797-816. PubMed ID: 26980704
[TBL] [Abstract][Full Text] [Related]
18. Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo.
Lu J; Chuan X; Zhang H; Dai W; Wang X; Wang X; Zhang Q
Int J Pharm; 2014 Aug; 471(1-2):525-35. PubMed ID: 24858391
[TBL] [Abstract][Full Text] [Related]
19. pH-responsive delivery vehicle based on RGD-modified polydopamine-paclitaxel-loaded poly (3-hydroxybutyrate-co-3-hydroxyvalerate) nanoparticles for targeted therapy in hepatocellular carcinoma.
Wu M; Zhong C; Zhang Q; Wang L; Wang L; Liu Y; Zhang X; Zhao X
J Nanobiotechnology; 2021 Feb; 19(1):39. PubMed ID: 33549107
[TBL] [Abstract][Full Text] [Related]
20. The preparation and characterization of anti-VEGFR2 conjugated, paclitaxel-loaded PLLA or PLGA microspheres for the systemic targeting of human prostate tumors.
Lu J; Jackson JK; Gleave ME; Burt HM
Cancer Chemother Pharmacol; 2008 May; 61(6):997-1005. PubMed ID: 17701176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
